MiR-101 Is Involved in Human Breast Carcinogenesis by Targeting Stathmin1
暂无分享,去创建一个
Y. Hu | Xu Ma | Hong-Fei Xia | Hong-Bin Wang | Fei-feng Li | Yi Cui | C. Hao | Rui Wang | Xiaoni Han | Hongfei Xia
[1] Sofie Nilsson,et al. Downregulation of miR-92a Is Associated with Aggressive Breast Cancer Features and Increased Tumour Macrophage Infiltration , 2012, PloS one.
[2] Hongjiang Wang,et al. Circulating MiR-125b as a Marker Predicting Chemoresistance in Breast Cancer , 2012, PloS one.
[3] Isaac Crespo,et al. A Novel Network Integrating a miRNA-203/SNAI1 Feedback Loop which Regulates Epithelial to Mesenchymal Transition , 2012, PloS one.
[4] Jun Yu,et al. Stathmin1 Plays Oncogenic Role and Is a Target of MicroRNA-223 in Gastric Cancer , 2012, PloS one.
[5] Alfredo Hidalgo-Miranda,et al. Identification and Pathway Analysis of microRNAs with No Previous Involvement in Breast Cancer , 2012, PloS one.
[6] Xu Ma,et al. MicroRNA‐181b and microRNA‐9 mediate arsenic‐induced angiogenesis via NRP1 , 2012, Journal of cellular physiology.
[7] Päivi Heikkilä,et al. MiR-34a Expression Has an Effect for Lower Risk of Metastasis and Associates with Expression Patterns Predicting Clinical Outcome in Breast Cancer , 2011, PloS one.
[8] R. Batchu,et al. MicroRNA-101 Inhibits Growth of Epithelial Ovarian Cancer by Relieving Chromatin-Mediated Transcriptional Repression of p21waf1/cip1 , 2011, Pharmaceutical Research.
[9] Ying Xu,et al. MicroRNA Expression and Regulation in Human Ovarian Carcinoma Cells by Luteinizing Hormone , 2011, PloS one.
[10] C. Sotiriou,et al. Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer , 2011, PloS one.
[11] Donglei Liu,et al. MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2 , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] B. Tannous,et al. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis , 2010, Oncotarget.
[13] H. Ruan,et al. MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. , 2010, European journal of cancer.
[14] J. Olson,et al. Targeting DNA-PKcs and ATM with miR-101 Sensitizes Tumors to Radiation , 2010, PloS one.
[15] S. Hsieh,et al. Stathmin1 overexpression associated with polyploidy, tumor‐cell invasion, early recurrence, and poor prognosis in human hepatoma , 2010, Molecular carcinogenesis.
[16] A. Lal,et al. MicroRNAs and their target gene networks in breast cancer , 2010, Breast Cancer Research.
[17] J. Lieberman,et al. miR-200 Enhances Mouse Breast Cancer Cell Colonization to Form Distant Metastases , 2009, PloS one.
[18] E. Spisni,et al. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. , 2009, Experimental cell research.
[19] Jian-Rong Yang,et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. , 2009, Cancer research.
[20] K. Imakawa,et al. A microRNA, miR-101a, controls mammary gland development by regulating cyclooxygenase-2 expression. , 2009, Differentiation; research in biological diversity.
[21] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[22] S. Varambally,et al. Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.
[23] N. Rajewsky,et al. Widespread changes in protein synthesis induced by microRNAs , 2008, Nature.
[24] D. Bartel,et al. The impact of microRNAs on protein output , 2008, Nature.
[25] Shushan Rana,et al. Stathmin 1: a novel therapeutic target for anticancer activity , 2008, Expert review of anticancer therapy.
[26] P. Schirmacher,et al. Protumorigenic overexpression of stathmin/Op18 by gain‐of‐function mutation in p53 in human hepatocarcinogenesis , 2007, Hepatology.
[27] Yong Zhao,et al. A developmental view of microRNA function. , 2007, Trends in biochemical sciences.
[28] Y. Miki,et al. Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer , 2007, Journal of Human Genetics.
[29] G. Atweh,et al. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer , 2006, Molecular Cancer Therapeutics.
[30] C. Burge,et al. Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.
[31] G. Atweh,et al. Stathmin Inhibition Enhances Okadaic Acid-induced Mitotic Arrest , 2001, The Journal of Biological Chemistry.
[32] G. Brattsand. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors , 2000, British Journal of Cancer.
[33] V. Ambros,et al. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. , 1999, Developmental biology.
[34] I. Bièche,et al. Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours , 1999, British Journal of Cancer.
[35] I. Bièche,et al. Overexpression of the stathmin gene in a subset of human breast cancer. , 1998, British Journal of Cancer.
[36] G. Atweh,et al. Role for protein phosphatases in the cell-cycle-regulated phosphorylation of stathmin. , 1998, The Biochemical journal.